Abstract: A composition comprising a mixture comprising or, alternatively, consisting of: at least one bacterial strain selected from a group comprising or, alternatively, consisting of bacterial strains belonging to the species Lactobacillus paracasei, Lactobacillus rhamnosus, Bifidobacterium bifidum and Bifidobacterium animalis subsp. Lactis, and preferably, at least one extract of at least one species of berries comprising a polyphenol fraction of said berries. and a related method wherein the composition is an immunomodulatory and anti-inflammatory agent are described.

Abstract: Compositions comprising a mixture comprising the bacterial strain Bifidobacterium bifidum MIMBb23sg or BbfIBS01 (DSM 32708), at least one or more bacterial strains selected from group A comprising the strains B. breve BbIBS01 (DSM 33231), B. breve BbIBS02 (DSM 33232), B. animalis subsp. lactis BlIBS01 (DSM 33233) and L. plantarum LpIBS01 (DSM 33234) and, optionally, at least one further bacterial strain selected from a bacterial strain L. casei DG® (CNCM I-1572) and a bacterial strain L. paracasei LPC-S01™ (DSM 26760) and related method for the treatment of gastrointestinal diseases, disorders or symptoms, in particular functional gastrointestinal disorders, such as, for example irritable bowel syndrome (IBS) are described.

Abstract: Bacterial strains including B. breve BbIBS01 (DSM 33231), B. breve BbIBS02 (DSM 33232), B. animalis subsp. lactis BIIBS01 (DSM 33233) and L. plantarum LpIBS01 (DSM 33234) are described. Furthermore, compositions are further described comprising a mixture of at least one or more of the aforementioned bacterial strains and, optionally, at least one further bacterial strain, selected from a bacterial strain L. casei DG® (CNCM I-1572) and bacterial strain L. paracasei LPC-S01™ (DSM 26760) and related method for the treatment of gastrointestinal diseases, disorders or symptoms, in particular functional gastrointestinal disorders, such as, irritable bowel syndrome (IBS).

Abstract: The present invention relates to a topical composition containing a probiotic and hyaluronic acid or a pharmaceutically acceptable salt thereof, for use in the treatment and/or prevention of inflammatory bowel disease.

Abstract: The present invention relates to a bacterial strain of Bifidobacterium bifidum MIMBb23 sg (=BbfIBSCM) DSM 32708, compositions comprising said bacterial strain and the use thereof in methods for the treatment of gastrointestinal disorders, in particular functional gastrointestinal disorders, such as, for example, irritable bowel syndrome (IBS) or inflammatory bowel diseases (IBDs).

Abstract: A composition is described comprising probiotics (live and viable or inactivated bacterial strains) and hyaluronic acid or a salt thereof and related use in prevention, treatment (therapeutic or cosmetic curative) or attenuation of at least one sign or symptom associated with, or caused by, skin aging. Use of the composition is also described in prevention or treatment (therapeutic or cosmetic curative) or attenuation of at least one sign or symptom associated with or caused by a reduction in the immune defences of the skin or by an inflammation/infection of the skin, such as an inflammation induced or caused by UV rays.

Abstract: The present invention relates to a liquid composition for use in the treatment of gastroesophageal reflux. The composition of the present invention comprises a mixture which comprises or, alternatively, consists of a combination of Aloe vera gel, hyaluronic acid and honey and, optionally, food or pharmaceutical grade additives and/or technological excipients. The composition of the present invention also relates to a medical device comprising a mixture which comprises or, alternatively, consists of a combination of Aloe vera gel, hyaluronic acid and honey and, optionally, food or pharmaceutical grade additives and/or technological excipients. Said composition or composition for a medical device being for use in the preventive and/or curative treatment of the symptoms associated with gastroesophageal reflux and the disease caused thereby, as well as for use in the preventive and/or curative treatment of gastroesophageal reflux disorders.

Abstract: The present invention relates to the use of probiotics, preferably one or more probiotic bacteria, to increase the absorption of proteins or the bioavailability thereof, preferably in individuals with increased protein and/or energy requirements, preferably elderly persons, children, pregnant women or athletes.

Abstract: A mixture (M) comprising or, alternatively consisting of: (i) water-soluble oligosaccharide, or a water-soluble complex carbohydrate, or mixtures thereof; (II) a casein; (ill) n3 and/or n6 fatty acids; (iv) an extract of Vaccinium macrocarpon. The present invention further relates to a pharmaceutical composition, or a food for special medical purpose (FSMP), or a medical device formulation or composition, or a dietary supplement comprising the aforementioned mixture (M), for use as medicament, or for use in the treatment of a chronic inflammatory bowel disease, in particular of states of malnutrition in subjects suffering from said chronic inflammatory bowel disease.

Abstract: The present invention relates to a liquid composition for use in the treatment of gastroesophageal reflux. The composition of the present invention comprises a mixture which comprises or, alternatively, consists of a combination of Aloe vera gel, hyaluronic acid and honey and, optionally, food or pharmaceutical grade additives and/or technological excipients. The composition of the present invention also relates to a medical device comprising a mixture which comprises or, alternatively, consists of a combination of Aloe vera gel, hyaluronic acid and honey and, optionally, food or pharmaceutical grade additives and/or technological excipients. Said composition or composition for a medical device being for use in the preventive and/or curative treatment of the symptoms associated with gastroesophageal reflux and the disease caused thereby, as well as for use in the preventive and/or curative treatment of gastroesophageal reflux disorders.

Abstract: The present invention relates to the use of specific strains of Lactobacillus paracasei or of a composition comprising said strains for the prevention and/or treatment of a physiopathological condition related to/associated with Clostridium difficile infection, preferably intestinal infections, or so-called CD-associated disease (CDAD) or CD infection (CDI).

Abstract: A method for characterising a tissue-engineered construct and the tissue-engineered construct are described. The characterisation method allows verification of viability, morphology, functionality and/or distribution of cells comprised in the tissue-engineered construct. The tissue-engineered construct has a scaffold with a lumen and at least one portion of the lumen lined with at least one functional and preferably continuous cell layer, that can be used for in vitro testing of medicinal products for human or animal use. A method for the in vitro testing of medicinal products for human or animal use performed with the tissue-engineered construct is also described.

Abstract: The present invention regards a composition based on bacteria belonging to the Lactobacillus paracasei species for use in the treatment and/or in the prevention of a pathological condition of the female urogenital tract, preferably a pathological condition of the female genital tract, more preferably of the vagina, said pathological condition being caused by or related with a vaginal microbiota imbalance or for treating and/or preventing the symptoms related with said pathological condition.

Abstract: The present invention regards a composition in powder form for oral inhalation, preferably for oral aspiration, comprising a mucolytic agent, preferably N-acetylcysteine. Furthermore, the present invention regards said composition for use in a method for the treatment of a mucus hypersecretion and of diseases, symptoms or disorders associated with it in a needy subject. Lastly, the present invention regards a device for administration, through inhalation route by means of oral aspiration, to said needy subject.

Abstract: The present invention regards a composition C1 in a form for topical administration comprising beclomethasone or a derivative thereof for use in a method for treating a disease, symptom and/or disorder deriving from an inflammation of the urogenital system and the lower urinary tract, in particular prostatitis of bacterial origin, inflammatory and painful symptoms associated with said bacterial prostatitis, vaginitis and inflammatory and painful symptoms associated with said vaginitis. Furthermore, the present invention regards a combination C for use in the aforementioned treatment method comprising said composition C1, comprising beclomethasone or a derivative thereof, and a composition C2 comprising a different active ingredient.

Abstract: The present invention relates to a composition comprising probiotics, preferably based on bacteria, in particular of the genus Lactobacillus, to be used for the purpose of preventing and/or treating the disorders affecting the skin, in particular inflammatory disorders, in particular autoinflammatory disorders of dermatological interest such as atopic dermatitis. Furthermore, the composition of the invention is useful for preventing and/or reducing the damage induced by UV radiation, in particular skin aging.

Abstract: The present invention relates to the use of probiotics to control the inflammatory process of the colon in subjects with structural modifications of the colon wall, preferably in subjects with diverticulosis, and affected by diverticular disease.

Abstract: The present invention refers to a model for in-vitro simulation of the behaviour of dysfunctional human vessels, such as for example vessels affected by aneurysm, stenosis or sclerosis plaques, as an instrument for testing medical devices and drugs with the aim of verifying effectiveness and safety thereof prior to use thereof on humans. Specifically, the present invention refers to an in vitro model of a substantially tubular-shaped vascular structure having dysfunctional anatomical and physiological characteristics simulating the same vascular structure of a healthy subject whose vascular structure has been damaged or deformed or deteriorated due to a damage selected from among the group comprising or, alternatively, consisting of aneurysm, stenosis, sclerosis plaques, forms of tumours or cardiomyopathies having the characteristics as claimed in the attached claims.

Abstract: Compositions, food products, methods and systems for use in increasing the blood bioavailability of amino acids derived from proteins, preferably proteins of plant origin, comprising a mixture M comprising or, alternatively, consisting of at least one bacterial strain, preferably Lactobacillus paracasei DG® CNCM I-1572 and/or Lactobacillus paracasei LPC-S01™ DSM 26760, and possibly. The compositions food products, methods and systems o the disclosure, can further comprise at least one protein, preferably proteins of plant origin, or a peptide or an amino acid, and in particular includes a food product comprising proteins, preferably of plant origin, and said mixture M of at least one bacterial strain.

Abstract: The present invention relates to a composition which comprises a mixture which comprises or, alternatively, consists of an extract (a) of a fruit of at least one plant of the genus Vaccinium and at least one ingredient (b) acceptable for pharmaceutical or food use and the use thereof in the prevention and/or treatment of diverticular disease or of a pathology deriving therefrom or correlated thereto.